找回密碼
 To register

QQ登錄

只需一步,快速開(kāi)始

掃一掃,訪問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Clinically Relevant Resistance in Cancer Chemotherapy; Borje Andersson,David Murray Book 2002 Springer Science+Business Media New York 200

[復(fù)制鏈接]
查看: 37131|回復(fù): 58
樓主
發(fā)表于 2025-3-21 18:01:54 | 只看該作者 |倒序?yàn)g覽 |閱讀模式
書目名稱Clinically Relevant Resistance in Cancer Chemotherapy
編輯Borje Andersson,David Murray
視頻videohttp://file.papertrans.cn/229/228314/228314.mp4
叢書名稱Cancer Treatment and Research
圖書封面Titlebook: Clinically Relevant Resistance in Cancer Chemotherapy;  Borje Andersson,David Murray Book 2002 Springer Science+Business Media New York 200
描述Over the last several decades, the introduction of new chemotherapeutic drugs and drug combinations has resulted in increased long- term remission rates in several important tumor types. These include childhood leukemia, adult leukemias and lymphomas, as well as testicular and trophoblastic tumors. The addition of high-dose chemotherapy with growth factor and hemopoietic stem cell support has increased clinical remission rates even further. For the majority of patients with some of the more common malignancies, however, palliation (rather than cure) is still the most realistic goal of chemotherapy for metastatic disease. The failure of chemotherapy to cure metastatic cancer is commonly referred to among clinicians as "drug resistance". This phenomenon can, however, often be viewed as the survival of malignant cells that resulted from a failure to deliver an effective drug dose to the (cellular) target because of anyone of or combination of a multitude of individual factors. Clinically, this treatment failure is often viewed as the rapid occurrence of resistance at the single cell level. However, in experimental systems, stable drug resistance is usually relatively slow to emerge.
出版日期Book 2002
關(guān)鍵詞DNA; cancer; cell; chemotherapy; leukemia; pharmacology; radiation; stem cell; tumor
版次1
doihttps://doi.org/10.1007/978-1-4615-1173-1
isbn_softcover978-1-4613-5428-4
isbn_ebook978-1-4615-1173-1Series ISSN 0927-3042 Series E-ISSN 2509-8497
issn_series 0927-3042
copyrightSpringer Science+Business Media New York 2002
The information of publication is updating

書目名稱Clinically Relevant Resistance in Cancer Chemotherapy影響因子(影響力)




書目名稱Clinically Relevant Resistance in Cancer Chemotherapy影響因子(影響力)學(xué)科排名




書目名稱Clinically Relevant Resistance in Cancer Chemotherapy網(wǎng)絡(luò)公開(kāi)度




書目名稱Clinically Relevant Resistance in Cancer Chemotherapy網(wǎng)絡(luò)公開(kāi)度學(xué)科排名




書目名稱Clinically Relevant Resistance in Cancer Chemotherapy被引頻次




書目名稱Clinically Relevant Resistance in Cancer Chemotherapy被引頻次學(xué)科排名




書目名稱Clinically Relevant Resistance in Cancer Chemotherapy年度引用




書目名稱Clinically Relevant Resistance in Cancer Chemotherapy年度引用學(xué)科排名




書目名稱Clinically Relevant Resistance in Cancer Chemotherapy讀者反饋




書目名稱Clinically Relevant Resistance in Cancer Chemotherapy讀者反饋學(xué)科排名




單選投票, 共有 0 人參與投票
 

0票 0%

Perfect with Aesthetics

 

0票 0%

Better Implies Difficulty

 

0票 0%

Good and Satisfactory

 

0票 0%

Adverse Performance

 

0票 0%

Disdainful Garbage

您所在的用戶組沒(méi)有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-21 21:02:49 | 只看該作者
The Role of Membrane Transporters in Cellular Resistance to Anticancer Nucleoside Drugs, in lipid bilayers, and their cellular uptake is mediated by integral membrane proteins. Nucleoside transporters serve as the cellular entry point for nucleoside salvage pathways. Some cell types use these pathways exclusively because they lack the ability to synthesize purine and pyrimidine nucleot
板凳
發(fā)表于 2025-3-22 01:08:06 | 只看該作者
地板
發(fā)表于 2025-3-22 05:42:24 | 只看該作者
The Glutathione System in Alkylator Resistance, can be intrinsically resistant to chemotherapy or, in other cases, develop resistance during the course of antineoplastic treatment. This acquired resistance is thought to occur through the selection of a subpopulation of resistant tumor cells as the tumor is exposed to chemotherapy. To complicate
5#
發(fā)表于 2025-3-22 11:44:50 | 只看該作者
6#
發(fā)表于 2025-3-22 14:11:27 | 只看該作者
Mechanisms of Repair of Interstrand Crosslinks in DNA,d War, making these agents among the oldest, and yet still most effective, anticancer drugs available in the clinic. The alkylation chemistry of these drugs was elucidated shortly after the War, and their cellular pharmacology was studied extensively during the 1970s and 1980s.. In contemporary chem
7#
發(fā)表于 2025-3-22 18:40:21 | 只看該作者
DNA Repair in Resistance to Bifunctional Alkylating and Platinating Agents,eutic agents. This rationale naturally extends to understanding the properties of tumor cells that make them responsive versus resistant to anticancer drugs. Many factors can contribute to the drug-resistant phenotype of individual tumor cells, and indeed, clinically relevant resistance in a given t
8#
發(fā)表于 2025-3-22 23:57:35 | 只看該作者
Leukemic Cell Insensitivity to Cyclophosphamide and other Oxazaphosphorines Mediated by Aldehyde Deeroxyifosfamide, on the part of the leukemias for which these agents are used is encountered all too often clinically. Increased detoxification of the oxazaphosphorines catalyzed by relatively elevated levels of any of several aldehyde dehydrogenases (ALDHs) present in target (malignant) cells could
9#
發(fā)表于 2025-3-23 02:11:53 | 只看該作者
Mechanisms of Resistance against Cyclophosphamide and Ifosfamide: Can they be Overcome without Sacrrst synthesized as an anticancer drug four decades ago, it continues to be widely used because of its unique efficacy against a broad range of human cancers.. To date, the structural isomer ifosfamide (IF, Ifos) is the most clinically useful CP analog, although its current applications in chemothera
10#
發(fā)表于 2025-3-23 07:18:28 | 只看該作者
Cellular Mechanisms of Cyclophosphamide Resistance: Model Studies in Human Medulloblastoma Cell Linldren’. Phase 2 trials in children with recurrent and newly diagnosed medulloblastoma have confirmed both clinical and radiographic responses to this alkylating agent.and a current Children’s Oncology Group international Phase 3 trial is comparing a cyclophosphamide-based regimen to a CCNU-based reg
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-8 06:39
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
肥东县| 文山县| 武清区| 房产| 汝阳县| 韶山市| 梅州市| 韶关市| 揭东县| 深州市| 贡觉县| 武强县| 岑巩县| 方山县| 年辖:市辖区| 台东市| 靖边县| 山丹县| 沁阳市| 永嘉县| 庆云县| 德阳市| 黄石市| 青海省| 博白县| 晋中市| 玉溪市| 定兴县| 龙海市| 连州市| 攀枝花市| 邳州市| 巴彦县| 苍山县| 长兴县| 二手房| 庆阳市| 界首市| 翁牛特旗| 炎陵县| 仙居县|